Pfizer Pricing
There will be a new Pfizer contract in place effective July 1, 2025 that offers CPP members an additional 3% discount on Trumenba® (MenB) and Penbraya™ (MenABCWY) purchases. In October 2024, the ACIP approved Penbraya™ as an option for patients who are recommended to receive both the MenACWY and the MenB shot at the same visit.
Updated pricing sheets can be obtained by contacting the CPP office at cpp@nationwidechildrens.org.
If you are considering incorporating this vaccine into your schedule, we recommend reaching out to your major payers to ensure adequate payment is in place for CPT code 90623. If you would like help with an analysis to forecast the financial impact of this schedule change, please reach out to CPP to discuss details and access helpful financial modeling tools.
Trumenba®/Penbraya™ Discounts
All members who are already enrolled in the Trumenba®/Penbraya™ opportunity will be automatically linked to discounts, you can simply check your invoice pricing.
If you are not currently enrolled in the Pfizer discount opportunity for Trumenba®/Penbraya™ and would like to be, visit the Pfizer contracting portal (www.primecontracts.pfizer.com) and choose the “Portfolio Program option”. Click here for step-by-step instructions.
Please feel free to reach out to us at CPP@NationwideChildrens.org if you have any questions.
Webinar
On June 16th, Pfizer will be hosting a free webinar, Risk of Invasive Meningococcal Disease in Adolescents and the Role of a Pentavalent MenABCWY Vaccine, with presenters Jaime E. Fergie MD, FAAP, FIDSA, FSHEA and Ruth M. Carrico PhD, DNP, APRN, FNP-C, CIC,FSHEA, FNAP, FAAN. Please pass along to physicians and staff that may be interested in the webinar.
For additional details click here and register for a time slot.
|